Evaluation of 89Zr-Labeled Human Anti-CD147 Monoclonal Antibody as a Positron Emission Tomography Probe in a Mouse Model of Pancreatic Cancer

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Sugyo, Aya ^a   Tsuji, Atsushi B ^a   Sudo, Hitomi ^a   Nagatsu, Kotaro ^a   Koizumi, Mitsuru ^a   Ukai, Yoshinori ^b   Kurosawa, Gene ^b   Zhang, Ming Rong ^a   Kurosawa, Yoshikazu ^b   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD147 ANTIGEN; MONOCLONAL ANTIBODY 059 053 GA 67; MONOCLONAL ANTIBODY 059 053 I 125; MONOCLONAL ANTIBODY 059 053 ZR 89; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL INTERACTION; CELL SPECIFICITY; CELL STRAIN ASPC 1; CELL STRAIN BXPC 3; CELL STRAIN MIA PACA 2; CELL STRAIN PANC 1; COMPETITIVE INHIBITION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING EQUIPMENT; DRUG DISTRIBUTION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MOLECULAR PROBE; MOUSE; NONHUMAN; PANCREAS CANCER; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD147; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; ZIRCONIUM;

AGOUTI PACA; MUS;

EID: 84875933701     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061230     Document Type: Article

References (32)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
3. Weidle UH, Scheuer W, Eggle D, Klostermann S, Stockinger H, (2010) Cancer-related issues of CD147. Cancer Genomics Proteomics 7: 157-169.
4. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, et al. (2006) High incidence of EMMPRIN expression in human tumors. Int J Cancer 119: 1800-1810.
5. Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, et al. (2001) Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 158: 1921-1928.
6. Chen ZN, Mi L, Xu J, Song F, Zhang Q, et al. (2006) Targeting radioimmunotherapy of hepatocellular carcinoma with iodine 131I metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 65: 435-444.
7. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, et al. (2007) A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 45: 269-276.
8. Kurosawa G, Akahori Y, Morita M, Sumitomo M, Sato N, et al. (2008) Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic. Proc Natl Acad Sci U S A 105: 7287-7292.
9. Kurosawa G, Sumitomo M, Ukai Y, Subere J, Muramatsu C, et al. (2011) Selection and analysis of anti-cancer antibodies for cancer therapy obtained from antibody phage library. Cancer Sci 102: 175-181.
10. Saga T, Endo K, Akiyama T, Sakahara H, Koizumi M, et al. (1991) Scintigraphic detection of overexpressed c-erbB-2 protooncogene products by a class-switched murine anti-c-erbB-2 protein monoclonal antibody. Cancer Res 51: 990-994.
11. Fu X, Guadagni F, Hoffman RM, (1992) A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A 89: 5645-5649.
12. Sogawa C, Tsuji AB, Sudo H, Sugyo A, Yoshida C, et al. (2010) C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model. Nucl Med Biol 37: 179-187.
13. Sudo H, Tsuji AB, Sugyo A, Ogawa Y, Sagara M, et al. (2012) ZDHHC8 knockdown enhances radiosensitivity and suppresses tumor growth in a mesothelioma mouse model. Cancer Sci 103: 203-209.
14. Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, et al. (2010) p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging 37: 250-259.
15. Nagatsu K, Suzuki H, Fukada M, Minegishi K, Tsuji A, et al. (2012) An alumina ceramic target vessel for the remote production of metallic radionuclides by in situ target dissolution. Nucl Med Biol 39: 1281-1285.
16. Sogawa C, Tsuji AB, Yoshida C, Inubushi M, Furukawa T, et al. (2012) Novel human monoclonal antibody against epidermal growth factor receptor as an imaging probe for hepatocellular carcinoma. Nucl Med Commun 33: 719-725.
17. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr, (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72: 77-89.
18. Yokoyama A, Ohmomo Y, Horiuchi K, Saji H, Tanaka H, et al. (1982) Deferoxamine, a promising bifunctional chelating agent for labeling proteins with gallium: Ga-67 DF-HSA: concise communication. J Nucl Med 23: 909-914.
19. Govindan SV, Michel RB, Griffiths GL, Goldenberg DM, Mattes MJ, (2005) Deferoxamine as a chelator for 67Ga in the preparation of antibody conjugates. Nucl Med Biol 32: 513-519.
20. Vosjan MJ, Perk LR, Roovers RC, Visser GW, Stigter-van Walsum M, et al. (2011) Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging 38: 753-763.
21. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, et al. (2010) 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 51: 1293-1300.
22. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, et al. (2005) 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 46: 1898-1906.
23. Verel I, Visser GW, Boellaard R, Boerman OC, van Eerd J, et al. (2003) Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 44: 1663-1670.
24. Nayak TK, Garmestani K, Milenic DE, Brechbiel MW, (2012) PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med 53: 113-120.
25. Zhang Z, Bian H, Feng Q, Mi L, Mo T, et al. (2006) Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther 5: 318-322.
26. Weinberg RA (2007) The Biology of Cancer. New York, NY: Garland Science.
27. Shah N, Zhai G, Knowles JA, Stockard CR, Grizzle WE, et al. (2012) 18F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts. Mol Imaging Biol 14: 237-244.
28. Xu J, Xu HY, Zhang Q, Song F, Jiang JL, et al. (2007) HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res 5: 605-614.
29. Holliger P, Hudson PJ, (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
30. Ju XZ, Yang JM, Zhou XY, Li ZT, Wu XH, (2008) EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer. Clin Cancer Res 14: 494-501.
31. Xue YJ, Lu Q, Sun ZX, (2011) CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med Oncol 28: 1363-1372.
32. Stenzinger A, Wittschieber D, von Winterfeld M, Goeppert B, Kamphues C, et al. (2012) High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer. Hum Pathol 43: 1471-1481.